Entire Portfolio
print

Composition of the portfolio as at March 31, 2015

Celgene   10.7%
Isis Pharmaceuticals   9.5%
Incyte   9.1%
Gilead   7.3%
Actelion   7.3%
Agios Pharmaceuticals   4.6%
Medivation   4.3%
Vertex Pharmaceuticals   4.1%
Radius Health   4.0%
Neurocrine Biosciences   3.3%
Puma Biotechnology   3.2%
Alexion Pharmaceuticals   3.0%
Receptos   2.7%
Synageva BioPharma   2.6%
Novo Nordisk   2.5%
Halozyme Therapeutics   2.4%
Regeneron Pharmaceuticals   2.3%
Alnylam Pharmaceuticals   2.3%
PTC Therapeutics   1.9%
Novavax   1.8%
Swedish Orphan Biovitrum   1.8%
Tetraphase Pharmaceuticals   1.4%
Tesaro   1.3%
Clovis Oncology   1.2%
Intercept Pharmaceuticals   1.1%
Cempra   1.1%
Infinity Pharmaceuticals   1.0%
Immunogen   0.7%
Probiodrug   0.6%
Theravance   0.3%
Achillion Pharmaceuticals   0.3%
Theravance Biopharma   0.2%
     
     
Radius Health Warrants 23.04.2018   0.1%
Radius Health Warrants 19.02.2019   0.1%
Merck & Co Inc Contingent Value Rights - ex Trius/Cubist   0.0%
     
Total Securities   CHF 3 728.4 mn
     
Other assets   CHF 19.3 mn
Other payables   CHF (42.2) mn
     
total shareholder's equity   CHF 3 705.3 mn
Treasury shares (in % of company) 1)   5.8%

 

1) Correspond to the total of all own shares held including the second trading line

News
23.06.2015
04.06.2015